The researchers found that among subclasses, IgG1 expression was most prominent in samples from patients with multiple myeloma, and expression of IgG1 changed significantly before, throughout, and ...

TORONTO -- A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...

Your doctor tells you your multiple myeloma is in remission. But what exactly does that mean? The first thing to understand is that being in remission is not the same thing as being cured. The ...